Mitoxantrone Liposome
Various Cancers
Phase 3Active
Key Facts
About CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group is a leading Chinese pharmaceutical company with a diversified portfolio spanning innovative drug development, generic medicines, and pharmaceutical manufacturing. Founded in 1997 and publicly traded on the Hong Kong Stock Exchange, the company has established itself as a major player in China's pharmaceutical industry with strong R&D capabilities and extensive manufacturing infrastructure. CSPC focuses primarily on oncology, CNS disorders, and metabolic diseases, with multiple products in clinical development and a robust commercial portfolio serving both domestic and international markets.
View full company profileOther Various Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Retifanlimab | Eli Lilly | Phase 2/3 |
| Imfinzi (durvalumab) | AstraZeneca | Approved |
| Lynparza (olaparib) | Merck | Commercial |
| Oncology Portfolio | Pfizer | Phase 1-3 |
| PD-1 Inhibitor | Akeso | Phase 2/3 |
| Biosimilar Bevacizumab | Cipla | Commercial |
| Tazverik (tazemetostat) | Eisai | Commercial |
| Oncology Generics | Aurobindo Pharma | Commercial |
| Opdivo (nivolumab) | Ono Pharmaceutical | Approved |
| Oncology APIs (e.g., Sorafenib, Lenalidomide) | Laurus Labs | Commercial/Filed |
| Tumor Marker Portfolio (PSA, CA125, etc.) | H.U. Group Holdings | Commercial |
| Logic-gated Switch-DARPins | Molecular Partners | Preclinical |